 Trimetrexate prostatic cancer preliminary observations use prostate-specific antigen acid phosphatase marker measurable hormone-refractory disease patients measurable hormone-refractory prostatic cancer trimetrexate TMTX Serial values prostate-specific antigen PSA acid phosphatase SAP response patients confidence interval partial remission median months range months Marker levels large variations discernible patterns Serial PSA SAP patients abnormal baseline values correlation measurable disease response patients Values exploratory data analysis technique medians averages Trends marker changes apparent Several decision rules use markers indices disease progression increase patient minimum value PSA SAP successive determinations progression cases trial TMTX modest activity prostatic cancer trials Biochemical markers reflect disease activity hormone-refractory disease changes biochemical markers sole end point efficacy clinical trials